Medpace (NASDAQ:MEDP) Given New $609.00 Price Target at Truist Financial

Medpace (NASDAQ:MEDP) had its target price increased by Truist Financial from $462.00 to $609.00 in a research report report published on Friday morning,Benzinga reports. The firm currently has a hold rating on the stock.

A number of other research analysts also recently weighed in on the stock. Wall Street Zen downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. TD Cowen raised their target price on Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research report on Friday. BMO Capital Markets lifted their price target on Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research note on Friday. Weiss Ratings reissued a “hold (c+)” rating on shares of Medpace in a report on Thursday, July 2nd. Finally, Robert W. Baird boosted their price objective on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a research report on Friday. Two investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $560.92.

Medpace Trading Down 0.7%

Shares of MEDP stock opened at $601.38 on Friday. The stock has a 50 day moving average of $492.09 and a 200 day moving average of $494.49. The stock has a market cap of $17.18 billion, a P/E ratio of 35.25, a P/E/G ratio of 2.96 and a beta of 1.15. Medpace has a twelve month low of $373.00 and a twelve month high of $677.90.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. During the same quarter in the prior year, the firm posted $3.10 EPS. The business’s quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, research analysts predict that Medpace will post 17.45 earnings per share for the current fiscal year.

Insider Activity at Medpace

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the sale, the general counsel directly owned 20,343 shares in the company, valued at $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 20.50% of the stock is owned by company insiders.

Institutional Trading of Medpace

Large investors have recently bought and sold shares of the business. AQR Capital Management LLC grew its position in shares of Medpace by 31.6% in the fourth quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock valued at $758,061,000 after purchasing an additional 324,293 shares in the last quarter. Wasatch Advisors LP lifted its position in Medpace by 14.0% during the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after buying an additional 116,354 shares in the last quarter. Geode Capital Management LLC lifted its position in Medpace by 3.8% during the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock worth $374,836,000 after buying an additional 24,625 shares in the last quarter. Invesco Ltd. boosted its stake in Medpace by 18.9% during the third quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock worth $276,313,000 after buying an additional 85,517 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in Medpace by 8.3% in the 1st quarter. Renaissance Technologies LLC now owns 504,668 shares of the company’s stock valued at $242,337,000 after buying an additional 38,760 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Key Stories Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace reported stronger-than-expected Q2 results, with EPS of $4.25 topping estimates and revenue of $707.3 million exceeding forecasts, reinforcing momentum in the business. MarketWatch article
• Positive Sentiment: The company raised FY 2026 guidance to EPS of $17.25-$17.95 and revenue of about $2.8 billion-$2.9 billion, signaling confidence in continued growth and backlog conversion. Benzinga article
• Positive Sentiment: Bookings and backlog trends improved, with commentary highlighting a rebound in the net book-to-bill ratio and better revenue visibility, which supports investor optimism about future quarters. Seeking Alpha article
• Neutral Sentiment: Truist raised its price target to $609 from $462 but kept a hold rating, while Robert W. Baird lifted its target to $624 and maintained a neutral stance, suggesting analysts see upside but are not turning fully bullish. Benzinga article
• Neutral Sentiment: The stock’s move to a 52-week high reflects strong recent performance, but one Zacks note questioned whether the rally can continue, indicating the market may now be weighing valuation against the improved fundamentals. Zacks article

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.